These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23289548)

  • 21. Effect of Long-term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial.
    Okereke OI; Vyas CM; Mischoulon D; Chang G; Cook NR; Weinberg A; Bubes V; Copeland T; Friedenberg G; Lee IM; Buring JE; Reynolds CF; Manson JE
    JAMA; 2021 Dec; 326(23):2385-2394. PubMed ID: 34932079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of a high eicosapentaenoic acid multinutrient supplement on measures of stress, anxiety and depression in young adults: Study protocol for NutriMOOD, a randomised double-blind placebo-controlled trial.
    Kelaiditis CF; Gibson EL; Dyall SC
    Prostaglandins Leukot Essent Fatty Acids; 2021 Oct; 173():102335. PubMed ID: 34461561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications.
    Viecelli AK; Pascoe E; Polkinghorne KR; Hawley C; Paul-Brent PA; Badve SV; Cass A; Heritier S; Kerr PG; Mori TA; Robertson A; Seong HL; Irish AB;
    BMC Nephrol; 2015 Jun; 16():89. PubMed ID: 26116581
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences between Japan and Taiwan in the treatment of pregnant women with depressive symptoms by omega-3 fatty acids: An open-label pilot study.
    Nishi D; Su KP; Usuda K; Chang JP; Chiang YJ; Guu TW; Hamazaki K; Nakaya N; Sone T; Hashimoto K; Hamazaki T; Matsuoka YJ
    Nutr Neurosci; 2019 Jan; 22(1):63-71. PubMed ID: 28752805
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials.
    Grosso G; Pajak A; Marventano S; Castellano S; Galvano F; Bucolo C; Drago F; Caraci F
    PLoS One; 2014; 9(5):e96905. PubMed ID: 24805797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials.
    Martins JG
    J Am Coll Nutr; 2009 Oct; 28(5):525-42. PubMed ID: 20439549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphatidylserine enriched with polyunsaturated n-3 fatty acid supplementation for attention-deficit hyperactivity disorder in children and adolescents with epilepsy: A randomized placebo-controlled trial.
    Rheims S; Herbillon V; Gaillard S; Mercier C; Villeuve N; Villéga F; Cances C; Castelnau P; Napuri S; de Saint-Martin A; Auvin S; Nguyen The Tich S; Berquin P; de Bellecize J; Milh M; Roy P; Arzimanoglou A; Bodennec J; Bezin L; Kassai B;
    Epilepsia Open; 2024 Apr; 9(2):582-591. PubMed ID: 38173190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Marine ω-3 Fatty Acid Supplementation vs Placebo in Reducing Incidence of Dry Eye Disease in Healthy US Adults: A Randomized Clinical Trial.
    Christen WG; Cook NR; Manson JE; Buring JE; Lee IM; Bubes V; Friedenberg G; Dushkes R; Smith D; Schaumberg DA;
    JAMA Ophthalmol; 2022 Jul; 140(7):707-714. PubMed ID: 35679030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder: study protocol for a randomized controlled trial.
    Dunlop BW; Rothbaum BO; Binder EB; Duncan E; Harvey PD; Jovanovic T; Kelley ME; Kinkead B; Kutner M; Iosifescu DV; Mathew SJ; Neylan TC; Kilts CD; Nemeroff CB; Mayberg HS
    Trials; 2014 Jun; 15():240. PubMed ID: 24950747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Omega-3 fatty acids for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial.
    Janczyk W; Socha P; Lebensztejn D; Wierzbicka A; Mazur A; Neuhoff-Murawska J; Matusik P
    BMC Pediatr; 2013 May; 13():85. PubMed ID: 23702094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects.
    Remans PH; Sont JK; Wagenaar LW; Wouters-Wesseling W; Zuijderduin WM; Jongma A; Breedveld FC; Van Laar JM
    Eur J Clin Nutr; 2004 Jun; 58(6):839-45. PubMed ID: 15164103
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial.
    Xue Y; Wang L; Liu T; Zhao T; Xie K; Guo J; Chen J; Tang H; Tang M
    J Affect Disord; 2024 Apr; 350():403-410. PubMed ID: 38244783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury.
    Rice TW; Wheeler AP; Thompson BT; deBoisblanc BP; Steingrub J; Rock P;
    JAMA; 2011 Oct; 306(14):1574-81. PubMed ID: 21976613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.
    Mocking RJ; Harmsen I; Assies J; Koeter MW; Ruhé HG; Schene AH
    Transl Psychiatry; 2016 Mar; 6(3):e756. PubMed ID: 26978738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clearance of fear memory from the hippocampus through neurogenesis by omega-3 fatty acids: a novel preventive strategy for posttraumatic stress disorder?
    Matsuoka Y
    Biopsychosoc Med; 2011 Feb; 5():3. PubMed ID: 21303552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Infant Fish Oil Supplementation Study (IFOS): design and research protocol of a double-blind, randomised controlled n--3 LCPUFA intervention trial in term infants.
    Meldrum SJ; D'Vaz N; Dunstan J; Mori TA; Prescott SL
    Contemp Clin Trials; 2011 Sep; 32(5):771-8. PubMed ID: 21718804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of a Novel Omega-3 and Omega-6 Fatty Acid Supplement on Dry Eye Disease: A 3-month Randomized Controlled Trial.
    Ng A; Woods J; Jahn T; Jones LW; Sullivan Ritter J
    Optom Vis Sci; 2022 Jan; 99(1):67-75. PubMed ID: 34882608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Body weight affects ω-3 polyunsaturated fatty acid (PUFA) accumulation in youth following supplementation in post-hoc analyses of a randomized controlled trial.
    Christian LM; Young AS; Mitchell AM; Belury MA; Gracious BL; Arnold LE; Fristad MA
    PLoS One; 2017; 12(4):e0173087. PubMed ID: 28379964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced Symptoms of Inattention after Dietary Omega-3 Fatty Acid Supplementation in Boys with and without Attention Deficit/Hyperactivity Disorder.
    Bos DJ; Oranje B; Veerhoek ES; Van Diepen RM; Weusten JM; Demmelmair H; Koletzko B; de Sain-van der Velden MG; Eilander A; Hoeksma M; Durston S
    Neuropsychopharmacology; 2015 Sep; 40(10):2298-306. PubMed ID: 25790022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial.
    Rondanelli M; Giacosa A; Opizzi A; Pelucchi C; La Vecchia C; Montorfano G; Negroni M; Berra B; Politi P; Rizzo AM
    J Am Coll Nutr; 2010 Feb; 29(1):55-64. PubMed ID: 20595646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.